NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 9, 2024
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In Capital · AccumulatedOtherComprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| (in millions) · Shares · $ | |||||||
| Balances at December 31, 2020 | 93.5 | $0.1 | $1,849.7 | $1.8 | $(725.4) | $1,126.2 | |
| Net income | — | — | — | — | 89.6 | 89.6 | |
| Other comprehensive loss, net of tax | — | — | — | (3.5) | — | (3.5) | |
| Stock-based compensation expense | — | — | 134.2 | — | — | 134.2 | |
| Issuances of common stock under stock plans | 1.4 | — | 27.5 | — | — | 27.5 | |
| Balances at December 31, 2021 | 94.9 | $0.1 | $2,011.4 | $(1.7) | $(635.8) | $1,374.0 | |
| Net income | — | — | — | — | 154.5 | 154.5 | |
| Other comprehensive loss, net of tax | — | — | — | (6.2) | — | (6.2) | |
| Cumulative-effect adjustment due to adoption of ASU 2020-06 | — | — | (106.8) | — | 74.5 | (32.3) | |
| Stock-based compensation expense | — | — | 173.1 | — | — | 173.1 | |
| Issuances of common stock under stock plans | 1.6 | — | 44.7 | — | — | 44.7 | |
| Balances at December 31, 2022 | 96.5 | $0.1 | $2,122.4 | $(7.9) | $(406.8) | $1,707.8 | |
| Net income | — | — | — | — | 249.7 | 249.7 | |
| Other comprehensive income, net of tax | — | — | — | 14.9 | — | 14.9 | |
| Stock-based compensation expense | — | — | 194.3 | — | — | 194.3 | |
| Issuances of common stock under stock plans | 2.2 | — | 65.3 | — | — | 65.3 | |
| Balances at December 31, 2023 | 98.7 | $0.1 | $2,382.0 | $7.0 | $(157.1) | $2,232.0 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.